Advertisement

European Journal of Law and Economics

, Volume 35, Issue 1, pp 61–85 | Cite as

The market of human experimentation

  • Roberto Ippoliti
Article

Abstract

How should experiments on humans be regulated and controlled? Is it possible to create an equilibrium between the optimal protection of patients’ rights and all the other interests involved? This paper analyzes the problem from a Law and Economics point of view and tries to develop a theoretical model that would provide a way to achieve that equilibrium, both in terms of effectiveness and efficiency, a model in which the interaction between different parties can lead to a market where information is exchanged for innovation. This paper is based on work that has been done up to now by other sciences, like medicine and bioethics, treating the issue with an alternative approach in order to propose an oversight system able to give an answer to this unsolved problem. This work is mainly aimed at defining the rules of the market in Europe, including its actors and their interactions using both a normative and a positive approach. Both the behavior of rational people and that of bounded ones are analyzed, as well as the strategies that can be applied against the latter by stronger parties. Finally, the public stakeholder’s role in preventing this from happening is analyzed.

Keywords

Pharmaceutical R&D Human experimentation Institutional Review Board Informed consent Intellectual property rights Medical researcher and research subject 

JEL Claasification

I11 

References

  1. Appelbaum, P. S., Roth, L. H., & Lidz, C. (1982). The therapeutic misconception: Informed consent in psychiatric research. International Journal of Law and Psychiatry, 5, 319–329.CrossRefGoogle Scholar
  2. Arrow, K. J. (1963). Uncertainty and the welfare economics of medical care. The American Economic Review, 3(5), 941–973.Google Scholar
  3. Calabresi, G. (1969). Reflection on medical experimentation in human. Daedalus, 98(2), 387–405.Google Scholar
  4. Christin-Maitre, S., Bouchard, P., & Spitz, I. M. (2000). Medical termination of pregnancy. New England Journal of Medicine, 342(13), 946–956.CrossRefGoogle Scholar
  5. Coleman, C. H. (2004). Rationalizing risk assessment in human subject research. Arizona Law Review, 46(1), 1–51.Google Scholar
  6. Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects. (1964/2008). 59thWMA General Assembly, Seoul, October.Google Scholar
  7. Dickert, N., Emanuel, E., & Grady, C. (2002). Paying research subjects: An analysis of current policies. Annals of Internal Medicine, 136(5), 368–373.Google Scholar
  8. Emanuel, E. J., Wendler, D., & Grady, C. (2000). What makes clinical research ethical? JAMA, 283(20), 2701–2711.CrossRefGoogle Scholar
  9. European Medicines Agency. (2001). Note for guidance on the investigation of bioavailability and bioequivalence, EMEA-CPMP, London, July CPMP/EWP/QWP/1401/98.Google Scholar
  10. Faden, R. R., Beauchamp, T. L., & King, N. M. P. (1986). A history and theory of informed consent. New York: Oxford University Press.Google Scholar
  11. Grady, C. (2001). Money for research participation: Does it jeopardize informed consent? American Journal of Bioethics, 1(2), 40–44.CrossRefGoogle Scholar
  12. Jolls, C., Sunstein, C. R., & Thaler, R. (1998). A behavioral approach to law and economics. Stanford Law Review, 50, 1471–1550.CrossRefGoogle Scholar
  13. Levin, R. C., Klevorich, A. K., Nelson, R. R., & Winter, S. G. (1987). Appropriating the returns from industrial research and development. Brookings papers on economic activity, Vol. 1987, No. 3, Special Issue on Microeconomics (pp. 783–831).Google Scholar
  14. Malani, A. (2006). Identifying placebo effects with data from clinical trials. Journal of Political Economy, 114(2), 236–256.CrossRefGoogle Scholar
  15. Moses, H., I. I. I., Ray Dorsey, E., Matheson, D. H. M., et al. (2005). Financial anatomy of biomedical research. Journal of the American Medical Association, 294(11), 1333–1342.CrossRefGoogle Scholar
  16. Nuremberg code of ethical human subjects research conduct. (1947).Google Scholar
  17. Physician’s Oath. (1968). Adopted by the General Assembly of the WMA, 22nd World Medical Assembly, Sydney, Australia, August.Google Scholar
  18. Sankar, P. (2004). Communication and miscommunication in informed consent to research. Medical Anthropology Quarterly, 18(4), 429–446.CrossRefGoogle Scholar
  19. Seeman, M. V. (2006–2007). Starvation in psychiatric institutions in Sweden. International Journal of Mental Health, 35(4), 81–87.Google Scholar
  20. The Association of the British Pharmaceutical Industry. (1994). Clinical trial compensation guidelines, ABPI, March.Google Scholar
  21. Von Neumann, J., et al. (1944). Theory of games and Economic Behavior. Princeton, NJ: Princeton University Press.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Real Collegio Carlo AlbertoMoncalieri, TurinItaly

Personalised recommendations